Epcoritamab单药或联合来那度胺一线治疗DLBCL的2期研究
这项开放标签、多中心、随机2期试验在11国44家医院入组不适合蒽环类化疗的初诊老年DLBCL患者,比较固定疗程epcoritamab单药与联合来那度胺。
要点
- 单药组≥3级不良事件以感染最常见(24%),严重不良事件发生率70%。
核心结论
- 固定疗程epcoritamab单药在不适合蒽环类化疗的初诊老年DLBCL患者中显示有前景的完全缓解率和可控的安全性。
研究设计与样本
- 开放标签、多中心、随机2期试验,在11个国家44家医院开展。
- 入组初诊CD20阳性大B细胞淋巴瘤、不适合蒽环类化疗(年龄≥80岁或≥75岁伴显著合并症)、Ann Arbor II-IV期、ECOG 0-2分的患者。
- 第1阶段按1:1随机分配至epcoritamab单药或epcoritamab联合来那度胺,按IPI(<3 vs ≥3)和ECOG(0-1 vs 2)分层;第2阶段扩展选定的方案。
主要发现
- 第1阶段单药组≥3级治疗中出现的不良事件最常见为感染(8/44,18%)和疲乏(6/44,14%);联合组为中性粒细胞减少(17/42,40%)和感染(16/42,38%)。
- 第1阶段单药组严重不良事件28例(64%),联合组34例(81%);治疗中出现死亡两组各6例(14%)。
- 所有接受epcoritamab单药治疗的患者中,≥3级治疗中出现的不良事件最常见为感染(16/66,24%)、中性粒细胞减少(8/66,12%)和高血压(7/66,11%);严重不良事件46例(70%)。
临床怎么用
- 对于不适合蒽环类化疗的初诊老年DLBCL患者,固定疗程epcoritamab单药可作为潜在的一线无化疗选择。
- 治疗期间需重点监测感染、中性粒细胞减少和高血压等不良事件,并关注严重不良事件及治疗相关死亡风险。
局限性
- 研究为2期试验,样本量有限,第1阶段每组44例,第2阶段单药组22例。
- 第1阶段与第2阶段完全缓解率存在差异,结果需进一步验证。
- 研究未报告无进展生存、总生存等长期疗效数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anthracycline-free regimens are needed for older adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL). We aim to evaluate the efficacy and safety of fixed-duration epcoritamab monotherapy versus epcoritamab with lenalidomide in this patient population. METHODS: This open-label, multicentre, randomised, phase 2 trial was conducted at 44 hospitals across 11 countries in Europe and Asia. Patients had newly diagnosed, histologically confirmed CD20-positive large B-cell lymphoma, were ineligible for anthracycline-based chemoimmunotherapy (age ≥80 or ≥75 years with clinically significant comorbidities), had Ann Arbor stage II-IV disease, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. In stage 1, patients were randomly assigned (1:1) to epcoritamab monotherapy or epcoritamab with lenalidomide using a validated interactive response technology system and stratified by the International Prognostic Index (<3 vs ≥3) and ECOG performance status (0-1 vs 2). Epcoritamab was administered subcutaneously using a two step-up dosing schedule (0·16 mg on cycle 1 day 1 and 0·8 mg on cycle 1 day 8), followed by full 48 mg doses once per week in 28-day cycles during cycles 1-3 and once every 4 weeks during cycles 4-12 for up to 12 cycles. Lenalidomide (10 or 20 mg) was given orally once a day on days 1-21 of 28-day cycles for up to 12 cycles. Based on stage 1, one of the treatment regimens was selected for expansion in stage 2. The primary endpoint was investigator-assessed complete response rate (as of the data cutoff on Dec 5, 2025; Lugano criteria) in the full analysis set (all randomly assigned patients in stage 1 and in all treated patients in stage 2). Safety was analysed in patients who received ≥1 dose of trial treatment. This study is registered with ClinicalTrials.gov, NCT05660967 (active, not recruiting). FINDINGS: Between March 8, 2023, and May 14, 2025, 111 patients were assessed for eligibility (88 in stage 1 and 23 in stage 2) and 108 were treated. Median age was 83·0 years (IQR 80·0-86·0). 51 (47%) of 108 were male, 57 (53%) were female, and 87 (81%) were White. In stage 1, 44 patients each were randomly assigned to epcoritamab monotherapy or epcoritamab with lenalidomide and two did not receive treatment. At data cutoff, the complete response rate in stage 1 was 63·6% (95% CI 47·8-77·6; in 28 of 44 patients) in the epcoritamab monotherapy group and 45·5% (30·4-61·2; in 20 of 44) in the epcoritamab with lenalidomide group. The most common treatment-emergent adverse events (grade ≥3) were infections (eight [18%] of 44 patients) and fatigue (six [14%]) with epcoritamab monotherapy versus neutropenia (17 [40%] of 42) and infections (16 [38%]) with epcoritamab with lenalidomide; with serious adverse events in 28 (64%) versus 34 (81%). Treatment-emergent deaths occurred in six (14%) patients in the monotherapy group (cytomegalovirus infection reactivation, COVID-19 pneumonia, SARS-COV-2 infection, tumour lysis syndrome, neuroendocrine tumour of the lung, tumour haemorrhage) and six (14%) in the combined group (pneumonia, COVID-19 pneumonia, sepsis, general physical health deterioration, multiple organ dysfunction syndrome, acute cardiac failure). Based on differences in complete response rates and safety, epcoritamab monotherapy was selected for stage 2 and one patient did not receive treatment. In the epcoritamab monotherapy group, the complete response rate was 45·5% (24·4-67·8; in ten of 22) in stage 2 and 57·6% (44·8-69·7; in 38 of 66) across stages 1 and 2. The most common treatment-emergent adverse events (grade ≥3) among all patients who received epcoritamab monotherapy were infections (16 [24%]), neutropenia (eight [12%]), and hypertension (seven [11%]); with serious adverse events in 46 (70%). Treatment-emergent deaths occurred in two (3%) patients in stage 2 (multiple organ dysfunction syndrome and acute respiratory failure). INTERPRETATION: Fixed-duration epcoritamab monotherapy showed promising complete response rates and a manageable safety profile in older adults with newly diagnosed DLBCL and comorbidities, with slight differences between stages 1 and 2. Continued investigation of epcoritamab as a first-line chemotherapy-free treatment option is warranted. FUNDING: Genmab and AbbVie.
引用
- Vitolo U, Burgues JMB, Duell J, et al. Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial. Lancet Haematol. 2026. PMID: 42285113. doi:10.1016/S2352-3026(26)00112-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。